MyWay – Patient Support

MyWay – Patient Support

Sanofi

Available on Google Play
3.6(203)
10,000+ installsFreeHealth & Fitness

Updated Feb 23, 2026 · v3.4.0

CompareView on Google Play
Screenshot 1
Screenshot 2
Screenshot 3
Screenshot 4
Screenshot 5

Personalized support for your treatment journey

Personalized support for your treatment journey. The MyWay app is a patient support tool designed to help you access DUPIXENT® (dupilumab) as quickly as possible, once you have a prescription, and to help you through your treatment journey. The app provides patient support program services, medication tracking, tools, and educational resources to help you stay on track with therapy, including: • Upcoming dose calendar • Healthcare Provider (HCP) visit calendar • Support documentation exchange with Dupixent MyWay patient support program services • Localized environment data Sanofi US is distributing this app on behalf of Sanofi and Regeneron Pharmaceuticals, Inc. See full Prescribing Information and Patient Information for DUPIXENT® https://www.regeneron.com/downloads/dupixent_fpi.pdf https://www.regeneron.com/downloads/dupixent_ppi.pdf TREATMENT • Insurance help through Dupixent MyWay patient support program services (benefit verification) • Financial assistance for eligible patients (copay card, utilization tracker) • Nurse resource (supplemental injection training) • Medication track (reminder features, step-by-step injection instructions) • Body map tracking and injection completion log • Refill reminders • Other medication reminders JOURNAL • Symptom tracking journal • Personalized symptom report to share with your doctor LEARNING • Patient materials (testimonial videos) SEPTEMBER 2024 US.DUP.24.09.0167

Released
February 21, 2024

2 years on Google Play

Version
3.4.0
Updated
Feb 23, 2026
Content Rating
Everyone
Installs
10,000+
Developer
Sanofi
Website
https://www.dupixent.com/frequently-asked-questions
Email
support@mywayappsupport.com
In-app purchases
No

This app isn't currently appearing in any tracked top charts.

Rating breakdown

5
116
4
9
3
13
2
7
1
53